Interferon-α-Conditioned Human Monocytes Combine a Th1-Orienting Attitude with the Induction of Autologous Th17 Responses: Role of IL-23 and IL-12

Stefano M. Santini, Caterina Lapenta, Simona Donati, Francesca Spadaro, Filippo Belardelli, Maria Ferrantini

Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy

Abstract

IFN-α exerts multiple effects leading to immune protection against pathogens and cancer as well to autoimmune reactions by acting on monocytes and dendritic cells. We analyzed the versatility of human monocytes conditioned by IFN-α towards dendritic cell differentiation (IFN-DC) in shaping the autologous T-helper response. Priming of naïve CD4 T cells with autologous IFN-DC in the presence of either SEA or anti-CD3, resulted, in addition to a prominent expansion of CXCR3+ IFN-γ-producing CD4 Th1 cells, in the emergence of two distinct subsets of IL-17-producing CD4 T cells: i) a predominant Th17 population selectively producing IL-17 and expressing CCR6; ii) a minor Th1/Th17 population, producing both IL-17 and IFN-γ. After phagocytosis of apoptotic cells, IFN-DC induced Th17 cell expansion and IL-17 release. Notably, the use of neutralizing antibodies revealed that IL-23 was an essential cytokine in mediating Th17 cell development by IFN-DC. The demonstration of the IFN-DC-induced expansion of both Th1 and Th17 cell populations reveals the intrinsic plasticity of these DC in orienting the immune response and provides a mechanistic link between IFN-α and the onset of autoimmune phenomena, which have been correlated with both IL-17 production and exposure to IFN-α.

Introduction

IFN-α has been recently recognized as an important factor in linking innate and adaptive immunity. In fact, through its rapid secretion by specialized cells, such as plasmacytoid DC (pDC), and concomitant capability to act on cells of innate and acquired immunity [1,2], IFN-α promotes the induction of immune responses, including auto-reactive responses. In fact, IFN-α has been considered as the driving factor in several human autoimmune diseases such as Systemic Lupus Erythematosus (SLE) [3], myositis, Sjogren’s syndrome and the initial phase of psoriasis [1].

IFN-α can contribute to the breaking of tolerance and to the induction/expansion of auto-reactive T and B cells through direct effects on these cells or by modulating immune functions through the induction of DC costimulatory molecules and soluble factors [1,4]. Interestingly, the association between an increased production and/or bioavailability of IFN-α and alterations in DC homeostasis has been indicated in various human inflammatory and autoimmune diseases. Of note, the Toll Like Receptor (TLR)-dependent production of IFN-α by pDC may play a central role in the pathogenesis of SLE [1,3] and psoriasis [3] by inducing the differentiation of monocytes into highly activated myeloid DC.

The pathogenetic role of IFN-α in autoimmune disorders has been traditionally attributed to its ability to polarize T-helper cells toward the Th1 type of immune response and to induce the generation/activation of effector immune cells [6]. However, the discovery of IL-23 and IL-17 and the recognition of the new IL-23/Th17 axis in the pathogenesis of a variety of inflammatory and autoimmune diseases [7,8] have led to reconsider the role played by cytokines other than IL-12, such as IFN-γ, TGF-β, IL-6, IL-1β, that are mainly produced by activated accessory cells and APCs, particularly DC. In this regard, however, the possible role of IFN-α and DC in the induction of a Th17 CD4+ T cell response has not yet been investigated.

As well as others [2, and references therein] have demonstrated that IFN-α induces the rapid differentiation of monocytes into highly active DC (IFN-DC), capable of promoting Th1 type immune responses through the expansion of CD4 and CD8 T cells producing large quantities of IFN-γ [9,10]. Further studies suggested that cytokines belonging to the IL-12 cytokine family (IL-23 and IL-27), could play a role in the Th1-promoting activity of IFN-DC [10].

In this study, we have investigated the interaction between IFN-DC and autologous naïve CD4 T cells. The characterization of the cytokine milieu produced by IFN-DC revealed the release of soluble factors known to promote Th17 differentiation. Consistently, IFN-DC induced a clear-cut Th17 response and IL-17 production. Since Th17 lymphocytes have been implicated in the
pathogenesis of autoimmune disorders, these findings are instrumental in understanding how IFN-α, by shaping DC functions including IL-23 release, can induce autoimmunity, thus leading to a more comprehensive vision of the role of this cytokine in the regulation of the immune response under both physiological and pathological conditions.

**Results**

**IFN-α-conditioned DC and induction of a Th1 type response in the presence of SEA**

In this study, two experimental systems were used in which human naïve CD4 T cells purified from peripheral blood were cocultured with autologous IFN-DC or IL-4-DC and stimulated or not with either the superantigen SEA Vβ specific [11], which activates a wide repertoire of T-cell receptors β variable chains (TCRV beta) with subsequent massive proliferation of CD4 T cells, or anti-CD3-coated beads.

We preliminary evaluated the ensemble of cytokines accumulating in the supernatant from DC cultures. The analysis of IFN-DC cytokine milieu showed the presence, in addition to IL-12 and IL-23 as previously reported [10], of high levels of TNF-α and IL-6, together with lower levels of IL-1β (Fig. 1A). Significantly lower or virtually undetectable levels of these cytokines were secreted by IL-4-DC (Fig. 1A).

We then determined the profile and amount of cytokines released in the supernatant of co-cultures stimulated or not with SEA. As shown in Fig. 1B, in the absence of SEA the naïve CD4 T cells secreted significantly higher levels of IFN-γ when co-cultured with autologous IFN-DC as compared to IL-4-DC. Stimulation with SEA resulted in a substantial increase in the production of IFN-γ in the co-cultures of naïve CD4 T cells with either IFN-DC or IL-4-DC. However, stimulation in the presence of IFN-DC induced the release of much greater amounts of this cytokine. Considerable amounts of IL-13 were released by the naïve CD4 T cells co-cultured with IL-4-DC, whereas very low levels of this cytokine were secreted by the naïve CD4 T cells co-cultured with IFN-DC in the presence of the superantigen. Notably, significantly higher levels of IL-23 were secreted by IFN-DC as compared to IL-4-DC upon co-cultivation with autologous naïve CD4 T cells.

![Figure 1. Cytokine production by IFN-DC and IL-4-DC and induction of a Th1 type response in naïve CD4 T cells stimulated with SEA in the presence of autologous DC.](image-url)
Intracellular IFN-γ and IL-4 staining performed on the expanded CD4 T cell population after restimulation with PMA/ionomycin, confirmed the explicit attitude of IFN-DC to strongly favor the development of IFN-γ-producing T cells (Fig. 1C). Likewise, the analysis of the co-expression of the surface markers CXCR3 or CD212 (IL-12Rβ1 chain) with the activation marker CD25 confirmed that IFN-DC efficiently expanded *bona fide* Th1 cells (Fig. 1D).

Of note, IFN-DC were superior with respect to IL-4-DC in inducing the expression of CD154 (CD40L), a marker of activated CD4 T cells. At both intermediate and high SEA concentrations, a higher percentage of CD154+ T cells was detected when the naïve CD4 T cells were co-cultured with autologous IFN-DC as compared to IL-4-DC (Fig. 2A), and CD154 membrane expression was far more intense in the co-cultures with IFN-DC as compared to those with IL-4-DC, in the presence of either SEA or anti-CD3 (Fig. 2B). Replacement of SEA with anti-CD3 coated beads for naïve CD4 T cell activation resulted in a further increase in CD154 expression exclusively on CD4 T cells co-cultured with IL-4-DC, suggesting that IFN-DC provide *per se* an optimal co-stimulation for efficient priming of CD4 T cells and maximal CD154 expression (Fig. 2).

IFN-α-conditioned DC produce a Th17 phenotype-promoting cytokine environment

Notably, the profile of IFN-DC cytokine production was strongly suggestive of a Th17 phenotype-promoting milieu (Fig. 1A), as IL-1β, IL-6, and TNF-α, together with IL-23, have been found to induce and sustain Th17 development [12,13]. In the light of the particular efficiency of IFN-DC in inducing high levels of CD154 in CD4 T cells (Fig. 2A and B) that are known to reciprocally activate DC through CD40-CD154 interaction, we then analyzed the cytokine production during the co-culture of naïve CD4 T cells with autologous DC in the absence or in the presence of either SEA or anti-CD3, especially focusing on IL-6 and IL-1β, which are known to play a key role in Th17 development [13]. As shown in Fig. 3, considerable levels of IL-6 (upper panel) and IL-1β (lower panel) were found in the cocultures of IFN-DC with naïve CD4 T cells in the absence of any stimulus, and a similar increase was induced upon stimulation with SEA or anti-CD3. In contrast, very low levels of IL-6 were secreted in the co-cultures of IL-4-DC with naïve CD4 T cells in the absence of stimuli, whereas IL-1β was virtually undetectable. An increase of IL-6 secretion in the co-cultures of naïve CD4 T cells with IL-4-DC occurred substantially in the presence of SEA and, to a lower extent, of anti-CD3, whereas IL-1β secretion was revealed only upon stimulation with SEA. Large amounts of TNF-α, ranging from 1,159 pg+/−306 to 1,592+/−254 (mean+/−SD values), were invariably present in all culture conditions and with both types of DC, while TGF-β was in any case undetectable (data not shown).

IFN-DC-driven induction of Th17 CD4 T cells

In the light of the cytokine milieu produced by IFN-DC, we evaluated whether these APC could favor the emergence of Th17 CD4 lymphocytes. In this set of experiments, anti-CD3-coated beads were used to stimulate the naïve CD4 T cells in the cocultures with autologous DC, to obtain a higher percentage of responding CD4 T cells and amplify the phenomenon. Remarkably, the FACS analysis demonstrated the concomitant expression of CCR4 and CCR6 (Fig. 4), that is assumed to identify the Th17 CD4 subset [12,13], on a fraction of CD4 T cells primed in the presence of autologous IFN-DC.

We have then assessed by CLSM analysis the expression of the transcriptional factors T-bet and RoR-γt, specific for the Th1 and Th17 subsets, respectively. The majority of CD4 T cells activated in the presence of autologous DC selectively expressed T-bet,
while RoR-γt was detected in only a minority of the cells (Fig. 5A, B). Consistently with the results indicating the IFN-DC-induced expansion of Th17 cells, the percentage of CD4 T cells expressing RoR-γt was higher in the cultures stimulated with anti-CD3-coated beads in the presence of autologous DC (mean 9.7 ± SD 1.8%) than in the co-cultures with IL-4-DC (mean 2.5 ± SD 2.4%) (Fig. 5A, B). The co-expression of T-het and RoR-γt was detected in about 1% of CD4 T cells expanded by anti-CD3-coated beads and IFN-DC, whereas it was virtually absent in the CD4 T cell-IL-4-DC co-cultures (Fig. 5B).

The production of IL-17 was evaluated after six days of CD4 T cell-DC co-culture in the presence of SEA or anti-CD3-coated beads by ELISA (Fig. 5C, top and middle panel) and by intracellular IL-17 staining to detect and quantify IL-17-producing cells by FACS analysis (Fig. 5D). The ELISA results clearly demonstrated the release of significantly higher amounts of IL-17 upon SEA or anti-CD3 stimulation of CD4 T cells in the presence of autologous IFN-DC, as compared to the co-culture with IL-4-DC. Considerable levels of IL-22, cytokine also associated to the Th17 phenotype, were secreted after stimulation of naive CD4 T cells with anti-CD3-coated beads in the presence of either type of autologous DC (Fig. 5C, bottom panel).

Intracellular staining for the detection of IFN-γ and IL-17 after restimulation of the expanded CD4 T cells with PMA/ionomycin, confirmed not only the efficiency of IFN-DC in promoting the expansion of IFN-γ-producing Th1 cells, but also their capability to induce the development of IL-17-producing T cells (Fig. 5D). A small but clearly detectable fraction of cells producing both IL-17 and IFN-γ was identified in the cultures of CD4 T cells stimulated with SEA or anti-CD3-coated beads in the presence of IFN-DC (Fig. 5D). We could not detect any expansion of Th17 cells nor IL-17 production when naïve CD4 T cells were activated with anti-CD3 plus anti-CD28 in the presence of IL-2 and IL-23 (data not shown), ruling out the possibility of the outgrowth of contaminating memory Th17 cells.

Role of IFN-DC-secreted cytokines in the induction of Th17 cell development

We then asked which IFN-DC cytokines were required for IL-17 induction in naïve CD4 T cells. As expected, the antibody blockade of an ensemble of cytokines (i.e. IL-1β, IL-6, TNF-α, and IL-12/IL-23) markedly inhibited IL-17 production (Fig. 6A), whereas neutralization of single cytokines did not significantly

![Figure 3. Release of IL-6 and IL-1β after co-culture of naïve CD4 T cells with autologous DC.](https://www.plosone.org/content/diff/10.1371/journal.pone.0017364/g003)

![Figure 4. Estimation of the emergence of Th17 cells by analysis of surrogate cell marker expression.](https://www.plosone.org/content/diff/10.1371/journal.pone.0017364.g004)
Figure 5. Expression of T-bet and RoR-γt transcription factors. IL-17 and IL-22 production by CD4 T cells stimulated in the presence of IFN-DC. A) CLSM analysis (central optical sections) was performed on CD4 T cells activated by anti-CD3-coated beads in the presence of autologous DC for six days to evaluate the expression of the transcription factors T-bet and RoR-γt (pseudo-color grey). Cell nuclei were stained with DAPI (blue). Insets represent background labelling of isotype control antibodies. One representative experiment out of three independently performed is reported. B) Co-expression of the transcription factors T-bet (red) and RoR-γt (green) in CD4 T cells activated with anti-CD3-coated beads in the presence of autologous DC for six days, as observed in a representative experiment out of three. Cell nuclei were stained with DAPI (blue). One representative experiment out of three independently performed is reported. C) Production of IL-17 and IL-22 in the culture supernatants of CD4 T cells stimulated with SEA or anti-CD3 in the presence of autologous DC for six days. The values represent the mean ± SD of four independent experiments. Statistical analysis was performed by Mann-Whitney test. * p<0.05. D) Production of IL-17 by a fraction of CD4 T cells, as demonstrated by intracellular cytokine staining. The dot plot analysis, representative of one out of five experiments, shows the intracellular IFN-γ and L-17 expression by CD4 T cells primed with SEA or anti-CD3 in the presence of autologous DC for six days. Upon activation with PMA/ionomycin in the presence of brefeldin-A for 5 hours, as described in Materials and Methods, cells were stained for the CD4 antigen, permeabilized and stained for intracellular IFN-γ and IL-17. Analysis was performed on electronically gated CD4+ T cells.

doi:10.1371/journal.pone.0017364.g005
prevent IL-17 production (data not shown). Interestingly, neutralizing antibodies against the IL-23p19 and the IL-12/IL-23p40 consistently and markedly inhibited IL-17 production in the co-cultures of naive CD4 T cells with IFN-DC (Fig. 6A). The combination of anti-p19 and anti-p40 antibodies was used to obtain the highest possible neutralization of IL-23 as, in our experimental setting, the addition of the anti-p19 antibody alone reproducibly resulted in only a limited neutralization of IL-23 and a slight inhibition of IL-17 production (data not shown). In contrast, the addition of both anti-p19 and anti-p40 antibodies resulted not only in a virtually complete disappearance of IL-23 (Fig. 6B, upper graph), but also in a sharp reduction of IFN-γ production in the co-cultures of naive CD4 T cells with autologous IFN-DC (Fig. 6B, lower graph). No significant increase in the inhibition of IL-17 production was observed when anti-IL-1β, anti-IL-6 or anti-TNF-α neutralizing antibodies were added together with the anti-p40 antibodies to the anti-CD3-activated naive CD4 T cell-IFN-DC co-cultures (Fig. 6A). Overall, these results together with the observation that much higher levels of IL-23 as compared to IL-12 were reproducibly detected in those co-cultures (data not shown), strongly indicate IL-23 as an essential cytokine in mediating human Th17 cell development by IFN-DC.

IFN-DC phagocytosis of apoptotic cells induces the production of Th17 inducing cytokines and IFN-γ

A recent study demonstrated that in mouse models the phagocytosis of apoptotic cells by DC in the presence of infection-induced signals promotes Th17 cell differentiation [14].

To investigate whether apoptotic cell-loaded IFN-DC could promote the expansion of IL-17-secreting cells, we cultivated naive CD4 T cells with autologous DC which had phagocytosed apoptotic melanoma (Me301) or cervical cancer (GaSki) cells. Interestingly, a notable increase in the percentage of CD154+ cells was induced by the co-cultivation of naive CD4 T cells with apoptotic cell-loaded IFN-DC (Fig. 7A). As shown in Fig. 7B, the uptake of apoptotic tumor cells induced a massive production of IL-6 in both IFN-DC and IL-4-DC, while the production of IL-23 was selectively induced in IFN-DC. On the contrary, only irrelevant levels of IL-1β could be detected in all the conditions tested. Upon culture of naive CD4 T cells with autologous DC loaded with apoptotic cells, high levels of IL-6 were found in the supernatants of all the different DC-CD4 T cells co-cultures, whereas IL-1β and IL-23 were produced mainly in the co-cultures of CD4 T cells with apoptotic cell-loaded IFN-DC (Fig. 7C). High levels of TNF-α were present in all culture conditions, while TGF-β was in all cases undetectable (data not shown).

Notably, the expansion of CCR6/CCR4 double positive cells clearly induced by stimulation with apoptotic cell-loaded IFN-DC (Fig. 7D), correlated with the levels of IL-17 detected in the corresponding culture supernatants (Fig. 7E), indicating the capability of IFN-DC which had phagocytosed apoptotic tumor cells to drive Th17 differentiation. Significantly higher levels of IFN-γ were induced following stimulation of naive CD4 T cells with apoptotic cell-loaded IFN-DC as compared to IL-4-DC.

Figure 6. Inhibition of IL-17 production by selective cytokine neutralization. A) Inhibition of IL-17 production by selected couples or cocktail of cytokine blocking antibodies. Naïve CD4+ T cells were activated with anti-CD3 coated beads and autologous DC at a cell ratio of 1:4 in the presence of the indicated couples of cytokine-neutralizing antibodies, or of the respective control isotypes. The presence of IL-17 was analyzed in the supernatants of cell cultures after 6 days by ELISA. The effect of the control isotypes couples on IL-17 production was not significantly different from that of the control isotypes cocktail. The values represent the mean +/- SD of three independent experiments. Statistical analysis was performed by Mann-Whitney test. * p<0.05. B) Inhibition of IFN-γ and IL-23 production by selective IL-23/IL-12 neutralization as compared to the inhibition obtained with the complete neutralizing cocktail, including antibodies to the p40 subunit of IL-12 and IL-23, p19 (IL-23), IL-1β, TNF-α and IL-6. Th values represent the mean +/- SD of three independent experiments. Statistical analysis was performed by Mann-Whitney test. * p<0.05.

doi:10.1371/journal.pone.0017364.g006
Figure 7. Induction of Th17 response by DC loaded with apoptotic cells. A) Representative dot plot analysis (one out of three) of CD154 induction in purified naïve CD4 T cells prior to use. CTR dot plots show the percentage of CD154 expression by CD4 T cells cultivated in the presence of autologous DC which had not phagocytosed apoptotic tumor cells. Analysis was performed on electronically gated CD4+ T cells. The percentage of early and late apoptotic tumor cells was evaluated by Annexin-V/propidium iodide staining. B) ELISA detection of IL-1β, IL-6 and IL-23 release by DC upon phagocytosis of apoptotic tumor cell lines. Analysis was performed after 18 hours from tumor cell uptake. The values represent the mean +/- SD of three independent experiments. C) ELISA detection of IL-1β, IL-6 and IL-23 in supernatants from co-culture of CD4 T cells with autologous DC which had phagocytosed apoptotic cells. After three days of co-culture, CD4 T cells were restimulated overnight with anti-CD3 coated beads. At day four the supernatant was collected for cytokine detection. All data are expressed as the mean +/- SD of three independent experiments. Statistical analysis was performed by Mann-Whitney test. * p<0.05. D) Dot plot analysis of CCR6/CCR4 expression by CD4+ T cells after six days of stimulation in the presence of DC fed with apoptotic tumor cells or autologous PBL. The results of one representative experiment out of three are shown. In all case, the analysis was performed on electronically gated CD4+ T cells. E) Evaluation of IL-22, IL-17 and IFN-γ production at day 4, after overnight restimulation of CD4 T cells with anti-CD3 coated beads. All data are representative of one out of three independent experiments performed with cells derived from different donors. The values represent the mean +/- SD of three independent experiments. Statistical analysis was performed by Mann-Whitney test. * p<0.05.

doi:10.1371/journal.pone.0017364.g007
counterparts. In contrast, high levels of IL-22 production were
detected in all conditions.

An expansion of CCR6/CCR4 double positive cells was found to occur also upon stimulation of naive CD4 T cells with IFN-DC fed with apoptotic autologous PBLs (Fig. 7D), arguing against the possibility that the Th17-inducing capability of apoptotic cell-loaded IFN-DC was dependent on tumor cell-specific factors.

Discussion

Here we have shown that IFN-α-conditioned DC can act as effective APC in driving the development of Th17 cells from autologous naive CD4 T cells. In fact, the priming of naive CD4 T cells with autologous IFN-DC in the presence of either SEA or anti-CD3, resulted, in addition to a prominent expansion of CXCR3+ IFN-γ-producing CD4 Th1 cells, in the emergence of two distinct subsets of IL-17-producing CD4 T cells: i) a predominant Th17 population selectively producing IL-17 and expressing CCR6; ii) a minor Th1/Th17 population, producing both IL-17 and IFN-γ (Fig. 5D).

The exact requirements of individual cytokines or their combination for human Th17 differentiation are still controversial [7]. Recent reports have indicated an important role of IL-1β, IL-6 and IL-25 in human Th17 differentiation [7,8,12–17]. Notwithstanding, human IL-17A-producing cells have been recently demonstrated to originate from CD161+ CD4+ T-cell precursors upon activation in the presence of IL-1β plus IL-23. The essential role of IL-23 either in inducing IL-17 production by human T cells [18] or in promoting the maintenance rather than the priming of the IL-17-secreting cell population has been also demonstrated [19]. However, the in vitro cytokine requirements for human Th17 differentiation are still matter of investigation, particularly under the physiological setting of naive CD4 T cells encountering antigen-presenting DC in the lymph nodes. Recent reports demonstrated that human DC differentiated in vitro from monocytes and activated through TLR [20] or inflammatory cytokines [21] were more efficient APC as compared to monocytes in inducing the expansion of IL-17-secreting cells upon stimulation of either allogeneic [20] or autologous T cells [21].

Here, we demonstrate, for the first time, that IFN-α-conditioned monocyte-derived DC act as highly efficient APC in inducing autologous IL-17-secreting Th17 cells, and that this effect is mediated by IL-23 and IL-12, as clearly indicated by the results of the neutralization experiments (Fig. 6). Our observation that much higher levels of IL-23 as compared to IL-12 were reproducibly detected in the cultures of naive CD4 T cells stimulated with anti-CD3-coated beads in the presence of IFN-DC (data not shown), strongly support the predominant role of IL-23 in mediating human Th17 cell development by IFN-DC. Although our results argue against an essential role of IL-1β in the IFN-DC-induced expansion of IL-17-secreting cells, we cannot rule out that the low basal levels of IL-1β secreted by IFN-DC are indeed playing an important role in the priming of naive CD4 T cells towards the IL-17-secreting phenotype, as also suggested by a recent report [20]. Notably, the IFN-DC capability to promote a Th17 response may also reside on their particular efficiency in inducing the expression of the CD40 ligand CD154 (Fig. 2 and 7A), as CD40-CD40L cross-talk has been recently reported to play a role in the establishment of the Th17 response [22].

Interestingly, at variance with previous reports [23,24], the high levels of IFN-γ secreted upon stimulation of naive CD4 T cells with IFN-DC did not appear to abrogate the capability of IFN-DC to induce the differentiation of Th17 cells from naive CD4 T cell precursors. Two opposite effects of IFN-γ on APC have been recently identified: the inhibition of the capacity to polarize the immune response towards the Th1 profile and the induction of IL-1β and IL-23 production, resulting in the expansion of memory Th17 cells [25]. The novel pathway of APC-mediated T cell differentiation indicated by our study is fully consistent with the dynamic model proposed by Kryczek and coworkers [25]. In particular, the ensemble of our data unravel a new scenario in which IFN-α, cytokines produced early in response to viral infections or other danger signals, can rapidly induce a polyfunctional DC type, i.e. the in vivo counterpart of IFN-DC, capable of secreting IL-12, IL-1β and IL-23 and concomitantly inducing the emergence of Th1, Th17 and Th1/Th17 CD4 T cells. The IFN-γ produced by the differentiated Th1 cells may trigger the further production of IL-23 by IFN-DC, promoting the expansion of memory Th17 cells. This scenario (Fig. 8) is consistent with the observation that the levels of IL-23 strongly increase when IFN-DC are co-cultured with activated CD4 T cells (Fig. 1B, 3B, and 7B), as a consequence of IFN-γ production induced by IFN-DC-secreted IL-12 and IL-23. Of note, in our study the neutralization of IL-12 and IL-23 resulted in a sharp reduction of IFN-γ secretion in the co-culture of naive CD4 T cells with autologous IFN-DC (Fig. 6). Taking into consideration the rapid exhaustion of IL-12 that we observed in the co-cultures of CD4 T cells with autologous IFN-DC (data not shown), it can be envisaged that, in the above proposed scenario, the IL-12 would act in the initial phase by priming the Th1 response, whereas the IL-23 would contribute to the maintenance of both the Th1 and the Th17 memory subsets, in agreement with previous reports [26,27].

The capability of IFN-DC to expand both a Th1 and a Th17 population is consistent with the new concept that both these subsets play a role in the pathogenesis of inflammatory and autoimmune diseases. The IFN-DC-mediated induction of CD4 T cells co-expressing IFN-γ and IL-17, the Th1/Th17 cells, is also interesting in the light of the evidence that in patients with certain autoimmune diseases (e.g. Crohn disease, uveitis), a considerable fraction of T cells secreting IL-17 in the tissue was described to express both IFN-γ and IL-17 [28,29].

Both IL-17 and IFN-α have been implicated in the pathogenesis of some autoimmune and inflammatory diseases. SLE represents a prototypic autoimmune disease characterized by a break of tolerance to self molecules, for which the possible pathogenetic role of IFN-α has been strongly emphasized [3]. Moreover, the seminal work by Banchereau’s group demonstrated that the IFN-α contained in the sera from SLE patients induces the differentiation of circulating monocytes into APC strongly resembling IFN-DC [30].

Rheumatoid arthritis (RA) [31], Crohn’s disease [32,33], and psoriasis [34] are other autoimmune inflammatory conditions in which an IFN-α/IL-23/IL-17 axis may be involved. Interestingly, activated DC infiltration has been shown in Crohn’s samples [32] with IL-23 mediating intestinal inflammation [33].

Our results clearly demonstrate that in an autologous human in vitro setting IFN-α acts on monocytes inducing their differentiation into APC capable of promoting the induction and expansion of both Th1 and IL-17-secreting, i.e. Th17 and Th1/Th17, subsets from naive CD4 T cells.

IFN-α represents the cytokine exhibiting the longest record of use in clinical oncology and many data support the concept that the antitumor response observed in IFN-treated cancer patients is mediated by an activation of immune cells, including T lymphocytes [6] and DC [35]. Intriguingly, in melanoma patients, a striking correlation between the clinical response and the development of signs of autoimmune reactions has been
demonstrated [36]. Notably, autoimmunity and effective tumor immunity often accompany one another, strongly suggesting that autoimmunity is a correlate of therapeutic benefit [37]. In the light of all this and of the recent evidence that Th17 cells play a role in immune-mediated control of tumors [38,39,40], our results may provide a mechanistic interpretation for the observed coupling of protective antitumor immunity with autoimmunity during IFN-α therapy. In fact, in previous studies we demonstrated that IFN-DC can effectively mediate the cross-priming of IFN-γ-secreting CD8 T cells against exogenous antigens [10], including apoptotic cell-derived antigens [41]. In the present study, we show that IFN-DC can also prime a Th17 response upon uptake of apoptotic cell-derived materials from tumor cells or autologous PBLs. Thus, we can assume that IFN-DC developing in vivo under pathological conditions or during IFN-α therapy can take-up apoptotic bodies from tumor cells and self cells as well, and can prime both Th1 and Th17 responses, thus leading to the expansion and activation of effectors T cells reactive against tumor-associated and self antigens.

The main research challenge in cancer immunotherapy is the development of effective and selective antitumor response, limiting immune attack to normal tissues. The understanding of how IFN-DC can induce a Th17 response upon uptake of apoptotic cell-derived materials from tumor cells or autologous PBLs. Thus, we can assume that IFN-DC developing in vivo under pathological conditions or during IFN-α therapy can take-up apoptotic bodies from tumor cells and self cells as well, and can prime both Th1 and Th17 responses, leading to the expansion and activation of effectors T cells reactive against tumor-associated and self antigens.

The main research challenge in cancer immunotherapy is the development of effective and selective antitumor response, limiting immune attack to normal tissues. The understanding of how IFN-DC can induce a Th17 cell response can open new perspectives for the treatment of some autoimmune diseases and for the development of more effective immunotherapy strategies in cancer patients.

Materials and Methods

**Ethic Statement**

Peripheral blood mononuclear cells utilized in this study derived from buffy coats obtained from healthy blood donors, as anonymously provided by the Immunohematology and Transfusional Center of Policlinico Umberto I, University “La Sapienza”, Rome. Written informed consent for the use of buffy coats for research purposes was obtained from blood donors by the Transfusional Center and both the informed consent form and procedure was approved by the Ethics Committee of Policlinico Umberto I. Data related to human samples were all analyzed anonymously.

**Cell preparation**

Peripheral blood mononuclear cells were purified by Ficoll density gradient centrifugation (Biochrom AG). Monocytes were isolated by immunomagnetic positive selection (MACS Cell Isolation Kits; Miltenyi Biotec) and plated at the concentration of 2×10⁶ cells/ml in RPMI medium (GIBCO BRL), supplemented with 10% FBS, 500 U/ml GM-CSF (Peprotech) and either 250 U/ml IL-4 (R&D Systems) for 5 days or 10,000 U/ml IFN-α2b (Intron A; Shering-Plough) for 3 days. Negatively selected PBLs were used to isolate naive CD4+ T cells by negative selection using the Naive CD4 T cell isolation kit II (Miltenyi Biotec). The isolated naive CD4+ T cells proved to be at least 95% pure.
Cytokine assays

Cytokine quantification was performed by commercial ELISA kits for: IL-1β, IL-4, IL-6, IFN-γ, TNF-α IL-12 (Endogen), IL-23 (Bender MedSystem), IL-13, IL-17, IL-22, TGF-β1 (R&D Systems) according to manufacturer instruction.

CD4+ T cells activation

DC, obtained as described above, were washed and cultured with autologous naïve CD4+ T cells (1:4 ratio) and 1 μg/ml SEA (Staphylococcal enterotoxin A, Sigma-Aldrich) for 6 days at 37 °C, or anti-CD3 coated beads (T cell activation/Expansion Kit, Miltenyi Biotech), using the manufacturer’s recommendations.

FACS analysis of surface markers and intracellular cytokine expression

Cells were stained with a panel of fluochrome-conjugated mAbs (BD Bioscience, R&D Systems) specific for T cells (anti-CD4, anti-CD25, anti-CXCR3, anti-CD212, anti-CCR6, anti-CCR4, anti-CD154).

Cytokine staining was performed after 6 days of DC naïve T cells culture (1:4 ratio). Cells were stimulated for 5 h with PMA (40 ng/ml) and ionomycin (500 ng/ml) (Sigma-Aldrich), in the presence of Golgi Plug (1 μg/ml) (BD Pharmingen) for the final 4 h of culture at 37 °C. Cells were fixed and permeabilized with BD Cytofix/Cytoperm Plus (BD Biosciences Pharmingen) and incubated at 4 °C for 30 min with FITC-labeled anti IFN-γ (BD Pharmingen), PE-labeled anti IL-4 (BD Pharmingen), or PE-labeled anti IL-17 (eBioscience), washed and analyzed on a FACScalibur cytometer with CellQuest software (Becton Dickinson).

Confocal laser scanning microscopy (CLSM) analysis.

CD4 T cells were seeded on cover glasses coated with poly-L-lysine (Sigma-Aldrich) Cells were fixed with paraformaldehyde (PFA) 3% (30 min, 4 °C), permeabilized by Triton X-100 (0.5% 10 min at room temperature, Sigma-Aldrich) and then stained at 37 °C with phycocerythrin (PE) anti mouse T-Bet Ab (eBioscience) and/or with rabbit polyclonal anti RORγt Abs (ABCAM), followed by Alexa Fluor 488 conjugated goat anti rabbit Abs (Molecular Probes). CLSM observations were performed with a Leica TCS SP2 AOBS apparatus. Image acquisition and processing were carried out using the Leica Confocal Software (Leica Lasertechnik). At least 1000 cells were analyzed in each field.

Neutralization Assay

DC were cultured with autologous naïve CD4+ T cells at a ratio of 1:4 and anti-CD3 activation beads (Miltenyi Biotech), in the presence of the following neutralizing antibodies: anti-IL-1β (10 μg/ml), anti-IL-6 (10 μg/ml), anti-TNF-α (10 μg/ml) (eBioscience), anti-IL-23p19 (10 μg/ml) (R&D Systems), anti-IL-12p40 (10 μg/ml) (Abcam), or the respective isotypic controls Abs. IL-17, IFN-γ and IL-23 production was analyzed after 6 days by ELISA (R&D Systems).

Induction of Th17 response by DC loaded with apoptotic tumor cells

DC were loaded with apoptotic Me501 (melanoma) and CaSkI (cervical cancer) tumor cells prior to co-culture. Apoptosis of Caski or Me501 cell lines was induced with UV-irradiation and monitored by Annexin-V-FITC Apoptosis detection Kit from PharMingen (Becton Dickinson Company, CA USA) and cultured with DC at a DC-tumor ratio of 1:1 for 18 hours. Tumor-loaded DC were then used to stimulate autologous T CD4 naïve cells at a S/R ratio of 1:1. After 4 days of culture, the presence of IL-17-producing T cells was monitored by ELISA after stimulation with anti-CD3 coated beads (T cell activation kit, MiltenyiBiotec) for additional 24 h.

Statistical analysis

All results are expressed as mean ± SD, whereas the statistical analysis was performed by Mann-Whitney test.

Author Contributions

Conceived and designed the experiments: SMS CL. Performed the experiments: SMS CL SD FS. Analyzed the data: SMS CL MF. Wrote the paper: MF SMS CL FB. Provided intellectual guidance on the project: FB MF. Supervised the design of experimental work: MF.

References

1. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN (2007) TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13: 543–551.
2. Santini SM, Lapenta C, Santodardo L, D’Agostino G, Belardelli F, et al. (2009) IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Handb Exp Pharmacol 198: 293–317.
3. Blanco P, Palucka AK, Pasquali V, Banchereau J (2008) Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 19: 41–52.
4. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, et al. (2006) Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176: 2074–2078.
5. Gilbert M, Lande R (2008) Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol 20: 401–407.
6. Belardelli F, Greseer I (1996) The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 17: 369–372.
7. Annunziato F, Cosmi L, Santarlasci V, Masp I, Liotta F, et al. (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204: 1849–1061.
8. Acosta-Rodriguez EV, Napoliati G, Lanavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8: 942–949.
9. Torchinsky MB, Garade J, Martin AP, Blander JM (2009) Innate immune recognition of infected apoptotic cells directs Th17 cell differentiation. Nature 458: 78–82.
10. Manel N, Unutmaz D, Littman DR (2006) The differentiation of human TH17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9: 641–649.
11. Volpe E, Servant N, Zollinger R, Bognar S, Hippe P, et al. (2008) A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human TH17 responses. Nat Immunol 9: 650–657.
12. Gerosa F, Baldini-Guerra B, Lyakh LA, Bontoni G, Eisin S (2008) Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 205: 1447–1461.
20. Benwell RK, DR Lee (2010) Essential and synergistic roles of IL1 and IL6 in human Th17 differentiation directed by TLR ligand-activated dendritic cells. Clin Immunol 134: 178–187.

21. Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A (2008) Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1) enriched in the bone marrow of patients with myeloma. Blood 112: 2878–2885.

22. Iezzi G, Sondergegerg I, Ampenberger F, Schmitz N, Marsland BJ (2009) CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci U S A 106: 876–881.

23. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123–1132.

24. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133–1141.

25. Kryczek I, Wei S, Gong W, Shu X, Szeliqa W (2008) Cutting Edge: IFN-gamma enable APC to promote memory TH17 and abate TH1 cell development. J Immunol 181: 5842–5846.

26. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715–725.

27. Trinchieri G, Pflanz S, Kastelein RA (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19: 641–644.

28. Brand S (2009) Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of crohn’s disease. Gut 58: 1152–1167.

29. Amadi-Obi A, Yu GR, Liu X, Mahdi RM, Clarke GL (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-22 and inhibited by IL-27/STAT1. Nat Med 13: 711–718.

30. Blanco P, Palacka AK, Gill M, Paschal V, Banchereau J (2000) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294: 1540–1543.

31. Lehrer MC, Jengbloed SL, Tan SW, Smeets TJ, McInnes IB (2008) Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP-dendritic cells with distinct cytokine profiles. Am J Pathol 172: 940–950.

32. Salm SY, Silva MA, Keita AV, Larsson M, Andersson P (2009) CD83+CCR7+ dendritic cells accumulate in the subepithelial dome and internalize translocated Escherichia coli HB101 in the Peyer’s patches of ileal Crohn’s disease. Am J Pathol 174: 82–90.

33. Hue S, Ahern P, Buonocore S, Kallberg MC, Cua DJ (2006) Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 203: 2473–2483.

34. Kryczek I, Bruce AT, Gutjonnson JE, Johnston A, Aphale A (2008) Induction of IL17-T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 181: 4733–4741.

35. Ferrantini M, Capone I, BelarkeF (2008) Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev 19: 95–107.

36. Gogas H, Ioannovich J, U Dafni (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709–718.

37. Kosu H, Akins M (2006) Autoimmunity and immunotherapy of cancer. New Engl J Med 354: 738–740.

38. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliqa W (2009) Phenotype, distribution, generation and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141–1149.

39. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787–798.

40. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362–373.

41. Parlato S, Romagnoli G, Spadaro F, Canini I, Sirabella P (2010) Loc-1 as natural IFN-gamma-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood 115: 1534–1563.